Galectin Therapeutics
GALT
75 hedge funds and large institutions have $31.1M invested in Galectin Therapeutics in 2020 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 24 increasing their positions, 17 reducing their positions, and 9 closing their positions.
64% more capital invested
Capital invested by funds: $19M → $31.1M (+$12.1M)
62% more call options, than puts
Call options by funds: $442K | Put options by funds: $273K
41% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 17
0.84% more ownership
Funds ownership: 16.98% → 17.82% (+0.84%)
3% less funds holding
Funds holding: 77 → 75 (-2)
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCB
Cutter & Co Brokerage
Ballwin,
Missouri
|
+$465K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
+$373K |
| 3 |
D.E. Shaw & Co
New York
|
+$198K |
| 4 |
Two Sigma Investments
New York
|
+$149K |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$131K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BWM
BT Wealth Management
Atlanta,
Georgia
|
-$118K |
| 2 |
BlackRock
New York
|
-$98.5K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$91.1K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$57.1K |
| 5 |
HS
HighVista Strategies
Boston,
Massachusetts
|
-$50K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BWM
76
BT Wealth Management
Atlanta,
Georgia
| – | -$118K | -60,000 | Closed |
|
|
HS
77
HighVista Strategies
Boston,
Massachusetts
| – | -$50K | -25,300 | Closed |
|
78
Renaissance Technologies
New York
| – | -$39K | -20,100 | Closed |
|
79
Victory Capital Management
San Antonio,
Texas
| – | -$28K | -14,782 | Closed |
|
|
BCM
80
Brookstone Capital Management
Wheaton,
Illinois
| – | -$20K | -10,150 | Closed |
|
81
Simplex Trading
Chicago,
Illinois
| – | -$4.39K | -1,744 | Closed |
|
GALT Hedge Fund Activity: Q2 2020 in Review
75 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q2 2020, worth a combined $31.1M — up 64% from $19M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of GALT and 8 opened new positions — a net loss of 1 holder — while 17 trimmed existing stakes and 24 added.
The largest buyer was Cutter & Co Brokerage, opening a new position worth an estimated $465K. The largest seller was BT Wealth Management, exiting entirely with an estimated $118K sold.
- 75 institutional investors held Galectin Therapeutics (GALT) as of Q2 2020, down from 77 in Q1 2020.
- Funds reported $31.1M of Galectin Therapeutics stock for Q2 2020, up 64% quarter-over-quarter.
- 8 funds opened new Galectin Therapeutics positions in Q2 2020 and 9 closed out, a net change of -1 holder.
- The largest Galectin Therapeutics buyer in Q2 2020 was Cutter & Co Brokerage, an estimated $465K added.
- The largest Galectin Therapeutics seller in Q2 2020 was BT Wealth Management, an estimated $118K sold.
Based on aggregated 13F filings for Q2 2020.